Skip to Main Content

Author Details

Adam Pavlicek
Monoceros Biosystems LLC
1998
50
31
PMIDPaper TitleJournal TitlePublished Year
36216931Anti-tumor efficacy of a potent and selective non-covalent KRAS<sup>G12D</sup> inhibitor.Nat Med2022
36216931Anti-tumor efficacy of a potent and selective non-covalent KRAS<sup>G12D</sup> inhibitor.Nat Med2022
33722854The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy.Mol Cancer Ther2021
33722854The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy.Mol Cancer Ther2021
31658955The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.Cancer Discov2020
31658955The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.Cancer Discov2020
31515477Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease.Nat Commun2019
31515477Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease.Nat Commun2019
28167506Lipid Nanoparticle-Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth.Mol Cancer Ther2017
28087069Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.Lancet2017
28167506Lipid Nanoparticle-Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth.Mol Cancer Ther2017
28087069Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.Lancet2017
25758165Anti-miR-21 Suppresses Hepatocellular Carcinoma Growth via Broad Transcriptional Network Deregulation.Mol Cancer Res2015
25758165Anti-miR-21 Suppresses Hepatocellular Carcinoma Growth via Broad Transcriptional Network Deregulation.Mol Cancer Res2015
25246611Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.J Natl Cancer Inst2014
25246611Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.J Natl Cancer Inst2014
24244628Predictive markers of efficacy for an angiopoietin-2 targeting therapeutic in xenograft models.PLoS One2013
24107449Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871).Mol Cancer Ther2013
24244628Predictive markers of efficacy for an angiopoietin-2 targeting therapeutic in xenograft models.PLoS One2013
24107449Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871).Mol Cancer Ther2013
22222631An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.Mol Cancer Ther2012
22806875Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.Clin Cancer Res2012
22745804A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation.PLoS One2012
22733720Exclusion of the 750-kb genetically unstable region at Xq27 as a candidate locus for prostate malignancy in HPCX1-linked families.Genes Chromosomes Cancer2012
22222631An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.Mol Cancer Ther2012
22806875Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.Clin Cancer Res2012
22733720Exclusion of the 750-kb genetically unstable region at Xq27 as a candidate locus for prostate malignancy in HPCX1-linked families.Genes Chromosomes Cancer2012
22745804A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation.PLoS One2012
21318402No alignment of cattle along geomagnetic field lines found.J Comp Physiol A Neuroethol Sens Neural Behav Physiol2011
21318402No alignment of cattle along geomagnetic field lines found.J Comp Physiol A Neuroethol Sens Neural Behav Physiol2011
21822054tRNA genes protect a reporter gene from epigenetic silencing in mouse cells.Cell Cycle2011
21822054tRNA genes protect a reporter gene from epigenetic silencing in mouse cells.Cell Cycle2011
20053295Statistical method on nonrandom clustering with application to somatic mutations in cancer.BMC Bioinformatics2010
20053295Statistical method on nonrandom clustering with application to somatic mutations in cancer.BMC Bioinformatics2010
19141594Human gamma-satellite DNA maintains open chromatin structure and protects a transgene from epigenetic silencing.Genome Res2009
19141594Human gamma-satellite DNA maintains open chromatin structure and protects a transgene from epigenetic silencing.Genome Res2009
18186519Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD).Hum Mutat2008
18186519Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD).Hum Mutat2008
17406683Evolutionary diversification of SPANX-N sperm protein gene structure and expression.PLoS One2007
17406683Evolutionary diversification of SPANX-N sperm protein gene structure and expression.PLoS One2007
18062188Production, purification and oxidative folding of the mouse recombinant prion protein.Folia Microbiol (Praha)2007
18062188Production, purification and oxidative folding of the mouse recombinant prion protein.Folia Microbiol (Praha)2007
16356584Retroposition of processed pseudogenes: the impact of RNA stability and translational control.Trends Genet2006
16356584Retroposition of processed pseudogenes: the impact of RNA stability and translational control.Trends Genet2006
16749933Positive selection on the nonhomologous end-joining factor Cernunnos-XLF in the human lineage.Biol Direct2006
16847692Identification of sequence motifs at the breakpoint junctions in three t(1;9)(p36.3;q34) and delineation of mechanisms involved in generating balanced translocations.Hum Genet2006
16427621CpG methylation suppresses transcriptional activity of human syncytin-1 in non-placental tissues.Exp Cell Res2006
16749933Positive selection on the nonhomologous end-joining factor Cernunnos-XLF in the human lineage.Biol Direct2006
16847692Identification of sequence motifs at the breakpoint junctions in three t(1;9)(p36.3;q34) and delineation of mechanisms involved in generating balanced translocations.Hum Genet2006
16427621CpG methylation suppresses transcriptional activity of human syncytin-1 in non-placental tissues.Exp Cell Res2006
  • 1 - 50 of 100

Recommended Authors

Center for Biomolecular Science and Engineering, University of California
Career Start Year 2002
Number of shared co-authors 1
Institute of Genetics and Cancer, University of Edinburgh
Career Start Year 2000
Number of shared co-authors 0
Inivata Ltd.
Career Start Year 1999
Number of shared co-authors 2
The Wellcome Trust Sanger Institute
Career Start Year 1998
Number of shared co-authors 3
National Human Genome Research Institute, National Institutes of Health
Career Start Year 1998
Number of shared co-authors 4
Institute of Genetics and Cancer, University of Edinburgh
Career Start Year 1997
Number of shared co-authors 0
College of Chemistry and Chemical Engineering, Hunan University
Career Start Year 1995
Number of shared co-authors 0
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1994
Number of shared co-authors 1
National Cancer Institute, National Institutes of Health
Career Start Year 1993
Number of shared co-authors 1
Present address: Inscripta Inc.
Career Start Year 1992
Number of shared co-authors 1
The University of Edinburgh
Career Start Year 1989
Number of shared co-authors 2
German Cancer Research Center (DKFZ)
Career Start Year 1988
Number of shared co-authors 0
European Bioinformatics Institute (EMBL-EBI)
Career Start Year 1987
Number of shared co-authors 1
Baylor College of Medicine
Career Start Year 1987
Number of shared co-authors 1
Baylor College of Medicine
Career Start Year 1987
Number of shared co-authors 5
Genomics Institute, University of California Santa Cruz
Career Start Year 1986
Number of shared co-authors 4
Vanderbilt-Ingram Cancer Center, Vanderbilt University
Career Start Year 1986
Number of shared co-authors 5
McGill University
Career Start Year 1986
Number of shared co-authors 0
Ontario Institute for Cancer Research
Career Start Year 1986
Number of shared co-authors 2
The Center for Genome Architecture, Baylor College of Medicine
Career Start Year 1986
Number of shared co-authors 0
National Human Genome Research Institute, National Institutes of Health
Career Start Year 1985
Number of shared co-authors 4
University of Adelaide
Career Start Year 1985
Number of shared co-authors 0
National Human Genome Research Institute, National Institutes of Health
Career Start Year 1984
Number of shared co-authors 3
Baylor College of Medicine
Career Start Year 1984
Number of shared co-authors 3
The Ohio State University
Career Start Year 1983
Number of shared co-authors 5
the University of Texas Health Science Center at Houston
Career Start Year 1982
Number of shared co-authors 0
HudsonAlpha Institute for Biotechnology
Career Start Year 1980
Number of shared co-authors 6
National Cancer Institute
Career Start Year 1980
Number of shared co-authors 2
Frederick National Laboratory for Cancer Research, Inc.
Career Start Year 1980
Number of shared co-authors 3
Institut Francois Jacob, CNRS, Universite Paris-Saclay
Career Start Year 1972
Number of shared co-authors 2

Collaborators

National Cancer Institute
Co-authored papers 8
National Cancer Institute
Co-authored papers 8
Korea Polar Research Institute
Co-authored papers 5
National Institute of Environmental Health Sciences
Co-authored papers 5
Oncology R&D
Co-authored papers 4
Co-authored papers 3
Co-authored papers 2
Massachusetts General Hospital
Co-authored papers 2
McGill University
Co-authored papers 2
Institute of Molecular Genetics of the Czech Academy of Sciences
Co-authored papers 2
Stanford Center for Biomedical Informatics Research, Stanford University
Co-authored papers 2
Institute of Biomedicine, University of Turku
Co-authored papers 2
Broad Institute of MIT and Harvard
Co-authored papers 2
Institute for Computer Science, Heinrich Heine University
Co-authored papers 1
Adaptive Biotechnologies
Co-authored papers 1
Dana-Farber Cancer Institute
Co-authored papers 1
NIH/National Institute of Ageing
Co-authored papers 1
Center for Cancer Research, National Cancer Institute
Co-authored papers 1
National Cancer Institute, National Institutes of Health
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Center for Applied Proteomics and Molecular Medicine, George Mason University
Co-authored papers 1
University of Pittsburgh School of Medicine.
Co-authored papers 1
GenomeDx Biosciences Inc.
Co-authored papers 1
Co-authored papers 1
Genomics Institute of the Novartis Research Foundation
Co-authored papers 1
Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington
Co-authored papers 1
Co-authored papers 1
University of British Columbia
Co-authored papers 1